Both epilepsy and anti‐seizure medications affect bone metabolism in children with self‐limited epilepsy with centrotemporal spikes

作者：Xiu‐Yu Shi, Jun Ju, Qian Lu, Lin‐Yan Hu, Yaping Tian, Guang‐Hong Guo, Z. J. Liu, Gefei Wu, Hong‐Min Zhu, Yu‐Qin Zhang, Dong Li, Li Gao, Yang Liu, Chunyu Wang, Jianxiang Liao, Jiwen Wang, Shuizhen Zhou, Hua Wang, Xiaojing Li, Jing‐Yun Gao, Li Zhang, Xiaomei Shu, Dan Li, Yan Li, Chunhong Chen, Xiu‐Ju Zhang, Jianmin Zhong, Qiong‐Xiang Zhai, Yan‐Hong Sun, Xuefeng Lin, Rong-Na Ren, Fei Yin, Yanhui Chen, Feiyong Jia, Zhixian Yang, Ju‐Li Wang, Zhe‐Zhi Xia, Li‐Wen Wang, Rong Luo, Li‐Ping Zou · 发表于：Epilepsia · 年份：2023 · DOI：10.1111/epi.17733 · 被引用次数：14 · 研究领域：Pharmacological Effects and Toxicity Studies、Epilepsy research and treatment、Diet and metabolism studies

Abstract Objective Bone metabolism can be influenced by a range of factors. We selected children with self‐limited epilepsy with centrotemporal spikes (SeLECTS) and lifestyles similar to those of healthy children to control for the confounding factors that may influence bone metabolism. We aimed to identify the specific effects of epilepsy and/or anti‐seizure medications (ASMs) on bone metabolism. Methods Patients with SeLECTS were divided into an untreated group and a monotherapy group, and the third group was a healthy control group. We determined the levels of various biochemical markers of bone metabolism, including procollagen type I nitrogenous propeptide (PINP), alkaline phosphatase (ALP), osteocalcin (OC), collagen type I cross‐linked C‐telopeptide (CTX), calcium, magnesium, phosphorus, parathyroid hormone (PTH), and vitamin D 3 (VD 3 ). Results A total of 1487 patients (from 19 centers) were diagnosed with SeLECTS; 1032 were analyzed, including 117 patients who did not receive any ASMs (untreated group), 643 patients who received only one ASM (monotherapy group), and 272 children in the healthy control group. Except for VD 3 , other bone metabolism of the three groups were different ( p < .001). Bone metabolism was significantly lower in the untreated group than the healthy control group (p < .05). There were significant differences between the monotherapy and healthy control group in the level of many markers. However, when comparing the monotherapy and untrea...